These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Challenges and opportunities in biomarker-driven trials: adaptive randomization. Park Y Ann Transl Med; 2022 Sep; 10(18):1035. PubMed ID: 36267794 [TBL] [Abstract][Full Text] [Related]
3. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology. Janiaud P; Serghiou S; Ioannidis JPA Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165 [TBL] [Abstract][Full Text] [Related]
5. Operational complexity versus design efficiency: challenges of implementing a phase IIa multiple parallel cohort targeted treatment platform trial in advanced breast cancer. Snowdon C; Kernaghan S; Moretti L; Turner NC; Ring A; Wilkinson K; Martin S; Foster S; Kilburn LS; Bliss JM Trials; 2022 May; 23(1):372. PubMed ID: 35526005 [TBL] [Abstract][Full Text] [Related]
6. Biostatistical and Logistical Considerations in the Development of Basket and Umbrella Clinical Trials. Yee LM; McShane LM; Freidlin B; Mooney MM; Korn EL Cancer J; 2019; 25(4):254-263. PubMed ID: 31335389 [TBL] [Abstract][Full Text] [Related]
7. Biomarker-Driven Oncology Clinical Trials: Novel Designs in the Era of Precision Medicine. Moore DC; Guinigundo AS J Adv Pract Oncol; 2023 Apr; 14(Suppl 1):9-13. PubMed ID: 37206904 [TBL] [Abstract][Full Text] [Related]
8. This is a platform alteration: a trial management perspective on the operational aspects of adaptive and platform and umbrella protocols. Schiavone F; Bathia R; Letchemanan K; Masters L; Amos C; Bara A; Brown L; Gilson C; Pugh C; Atako N; Hudson F; Parmar M; Langley R; Kaplan RS; Parker C; Attard G; Clarke NW; Gillessen S; James ND; Maughan T; Sydes MR; Trials; 2019 May; 20(1):264. PubMed ID: 31138317 [TBL] [Abstract][Full Text] [Related]
9. Challenges, opportunities, and innovative statistical designs for precision oncology trials. Yin J; Shen S; Shi Q Ann Transl Med; 2022 Sep; 10(18):1038. PubMed ID: 36267789 [TBL] [Abstract][Full Text] [Related]
10. An overview of precision oncology basket and umbrella trials for clinicians. Park JJH; Hsu G; Siden EG; Thorlund K; Mills EJ CA Cancer J Clin; 2020 Mar; 70(2):125-137. PubMed ID: 32031692 [TBL] [Abstract][Full Text] [Related]
11. Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials. Lu CC; Li XN; Broglio K; Bycott P; Jiang Q; Li X; McGlothlin A; Tian H; Ye J Ther Innov Regul Sci; 2021 Nov; 55(6):1145-1154. PubMed ID: 34160785 [TBL] [Abstract][Full Text] [Related]
12. Design and analysis of umbrella trials: Where do we stand? Ouma LO; Wason JMS; Zheng H; Wilson N; Grayling M Front Med (Lausanne); 2022; 9():1037439. PubMed ID: 36313987 [TBL] [Abstract][Full Text] [Related]
15. Utility of adaptive strategy and adaptive design for biomarker-facilitated patient selection in pharmacogenomic or pharmacogenetic clinical development program. Wang SJ J Formos Med Assoc; 2008 Dec; 107(12 Suppl):19-27. PubMed ID: 19129042 [TBL] [Abstract][Full Text] [Related]